Robert Keyes, MD
Geriatric Medicine · Cincinnati, OHNPI 1437265287
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $274 and has fallen 53.9% since, to $126 in 2024.
Across 57 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$196
- Amgen$182
- Merck$72
- Lilly USA, LLC$61
- Lundbeck LLC$58
- Teva Pharmaceuticals USA, Inc.$51
- plus $345 from 14 others
Across 23 payments — averaging $27,243 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$627K
What the payments were for
- Food & beverage$94398%
- Education$212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $196 |
| Amgen | 12 | $182 |
| Merck | 3 | $72 |
| Lilly USA, LLC | 3 | $61 |
| Lundbeck LLC | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 4 | $51 |
| Eisai Inc. | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Abbott | 2 | $40 |
| Corium, LLC | 2 | $32 |
| Biogen | 1 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| UCB, Inc. | 1 | $16 |
| Pfizer | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| AbbVie | 1 | $12 |
How this compares
$965 in reported general payments places this provider in the 75th percentile of 146 geriatric medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 86 | $49,426 |
| EliquisApixaban | 48 | $32,268 |
| XareltoRivaroxaban | 92 | $17,541 |
| BelsomraSuvorexant | 39 | $16,798 |
| GemtesaVibegron | 16 | $12,978 |
| TradjentaLinagliptin | 13 | $10,702 |
| MyrbetriqMirabegron | 36 | $9,957 |
| Rivastigmine | 39 | $6,560 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,851 |
| Duloxetine Hcl | 236 | $4,778 |
| Memantine Hcl ErMemantine Hcl | 45 | $4,656 |
| RivastigmineRivastigmine Tartrate | 49 | $4,574 |
| Memantine Hcl | 101 | $2,550 |
| KerendiaFinerenone | 15 | $2,458 |
| Divalproex Sodium | 132 | $2,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $196 | $49,42686 claims |
| PfizerEliquis | $13 | $32,26848 claims |
| Johnson & JohnsonXarelto | $13 | $17,54192 claims |
| MerckBelsomra | $72 | $16,79839 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $22 | $12,97816 claims |
| Lilly USA, LLCOlanzapine | $61 | $1,20549 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 146 geriatric medicine providers in Ohio.
Other geriatric medicine in Cincinnati
- James FidelholtzCincinnati$15K
- Milla KarevCincinnati$5K
- Amanda JudeCincinnati$4K
- Emmanuel RiveraCincinnati$2K
- Syed MoqeethCincinnati$676
- Shachi SinghCincinnati$426
- Jeffrey LeksonCincinnati$373
- Amanda ArnoldCincinnati$310
- Meenakshi PatelCenterville$644K
- Daniel CannoneWadsworth$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.